+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cell and Gene Therapy Bioassay Services Market by Type of Therapy, Therapeutic Area, Scale of Operation and Geography: Industry Trends and Global Forecasts, 2021-2030

  • PDF Icon

    Report

  • 310 Pages
  • January 2022
  • Region: Global
  • Roots Analysis
  • ID: 5557563
Description Jump to:
Given the various advantages of cell and gene therapies and their ability to address the underlying causes of serious clinical conditions, the preference for such therapeutic modalities has increased over the years. As a result, several cell and gene therapies have been developed and approved for the treatment of a wide range of disease indications. In fact, at the time of this report’s publication, more than 30 such therapies had been approved and over 1,200 therapeutic leads are under evaluation in different stages. Owing to their rising popularity, these upcoming advanced therapeutic products are on the verge of becoming one of the highest valued therapeutic segments within the biopharmaceutical industry. Having said that, as is the case for all biological products, the development of cell and gene therapies is a complex, challenging and cost intensive process. Outsourcing is, therefore, a preferred operational model, with cell and gene therapy innovators relying heavily on specialty contract service providers to handle various aspects of their product development and manufacturing operations. In fact, over three quarters of the biopharmaceutical companies prefer to outsource their operations to the contract service providers and a large part of their expenditure goes to outsourcing services. Amongst the various operations, the outsourcing of analytical testing services, including environment testing, bioanalytical testing, analytical testing, chemistry and stability testing, method development and validation, and product characterization, has witnessed significant rise in recent years.  

The rising demand for outsourcing bioanalytical services has prompted the emergence of several contract research organizations that claim to offer bioassay services for cell and gene therapies. These companies usually have relatively more experience and are well equipped with the instruments and technological platforms to offer both pre-developed and customized bioassays. In fact, these companies assist in bringing out the maximum efficiency of study design by offering several cost benefits and reducing the associated timelines. Given the benefits of outsourcing the bioassay services and the ongoing efforts of service providers to further improve / expand their respective offerings, we believe that the cell and gene therapy bioassay services market is likely to evolve at a steady pace, till 2030.


Scope of the Report



The “Cell and Gene Therapy Bioassay Services Market by Type of Therapy (Cell Therapy and Gene Therapy), Therapeutic Area (Oncological Disorders, Infectious Diseases, Autoimmune Disorders, Rare / Genetic Disorders, Cardiovascular Disorders, Metabolic Disorders, Blood Disorders, Neurological Disorders, Ophthalmic Disorders and Other Therapeutic Areas), Scale of Operation (Discovery, Preclinical and Clinical) and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current landscape and the likely future potential of cell and gene therapy bioassay service providers, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.


In addition to other elements, the study includes:


  • A detailed assessment of the overall market landscape of the cell and gene therapy bioassay services market, providing information on their year of establishment, company size, location of headquarters, location of bioanalytical facilities, type of offering (in vitro and in vivo), type of bioassay(s) offered (pre-developed assay and customized assay), type of bioanalytical services (immunoassay, potency assay, qualitative PCR, digital droplet PCR, flow cytometry, ELISA, immunochemistry and others) and application area (cell therapy, gene therapy and others).
  • A detailed competitiveness analysis of the cell and gene therapy bioassay service providers based in different geographies, by taking into consideration their service strength (in terms of bioassay offering(s) and number of bioanalytical services offered), service applicability (in terms of number of bioassays offered and application area) and supplier strength (in terms of years of experience in this field and company size).
  • Tabulated profiles of key players offering a wide range of cell and gene therapy bioassay services across North America, Europe and Asia-Pacific. Each profile includes an overview of the company, financial information (if available), details of its cell and gene therapy bioassay services portfolio, types of offerings, type of bioassay(s) offered, types of bioanalytical services offered, application area, location of bioanalytical facilities, recent developments and an informed future outlook. 
  • An insightful contemporary market trend analysis, featuring the distribution of cell and gene therapy service providers by type of bioanalytical services offered and application area and an analysis of cell and gene therapy service providers, based on type of bioassay and types of bioanalytical services offered. Further, the chapter also features a schematic world map representation, highlighting the location of bioanalytical facilities of cell and gene therapy bioassay service providers. 
  • A detailed analysis of the global events attended by the service providers, based on year of event, type of event, type of services involved and application area, and strategic initiatives taken by various cell and gene therapy bioassay service providers. 
  • A case study of the overall landscape of cell and gene therapy therapeutics market, based on a number of parameters. The market landscape of cell therapies, features distribution of cell therapies across phase of development, therapeutic area and type of developer. Further, the market landscape of cell therapies, features distribution of gene therapies across phase of development of pipeline candidates and key therapeutic areas. The chapter also features information on the developers involved in the domain of cell and gene therapies.
  • An in-depth analysis of more than 260 cell therapy developers that are anticipated to partner with cell and gene therapy bioassay service providers and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other cell therapy capabilities.
  • An in-depth analysis of nearly 190 gene therapy developers that are anticipated to partner with cell and gene therapy bioassay service providers and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.


One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of cell and gene therapy bioassay services market. We have provided an informed estimate of the evolution of the market for the period 2021-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of therapy (cell therapy and gene therapy), [B] therapeutic area (oncological disorders, infectious diseases, autoimmune disorders, rare / genetic disorders, cardiovascular disorders, metabolic disorders, blood disorders, neurological disorders, ophthalmic disorders and other therapeutic areas), [C] scale of operation (discovery, preclinical and clinical) and [D] geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report are backed by a deep understanding of key insights generated from both secondary and primary research. The information presented in this study was also influenced by discussions held with senior stakeholders in this industry.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.


Key Questions Answered


  • Who are the leading services providers offering bioassay services related to cell and gene therapies?
  • What is the relative competitiveness of different cell and gene therapy bioassay service providers?
  • Which is the commonly offered bioanalytical service (immunoassay, potency assay, qualitative PCR, digital droplet PCR, flow cytometry, ELISA, immunochemistry and others) related to cell and gene therapy?
  • What are the key trends within the cell and gene therapy bioassay service providers market?
  • What kind of initiatives are being taken by stakeholders engaged in this domain?
  • Which players are likely to partner with cell and gene therapy bioassay service providers?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to teleradiology services market?

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Bioassays
3.3. Cell and Gene Therapy Bioassays
3.4. Importance of Bioassays in Cell and Gene Therapy
3.5. Challenges Related to Cell and Gene Therapy Bioassays
3.6. Role of Contract Service Providers and Prevalent Outsourcing Trends
3.7. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell and Gene Therapy Bioassay Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Location of Bioanalytical Facilities
4.2.6. Analysis by Type of Bioassay(s) Offered
4.2.7. Analysis by Types of Offering(s) of Bioassay
4.2.8. Analysis of Type of Bioanalytical Service(s) Offered
4.2.9. Analysis by Application Area
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Key Parameters
5.4. Competitiveness Analysis: Companies Offering Cell and Gene Therapy Bioassay Services in North America
5.5. Competitiveness Analysis: Companies Offering Cell and Gene Therapy Bioassay Services in Europe and Asia-Pacific
6. CELL AND GENE THERAPY BIOASSAY SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter Overview
6.2. CCRM
6.2.1. Company Overview
6.2.2. Cell and Gene Therapy Bioassay Service Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Nexelis
6.3.1. Company Overview
6.3.2. Cell and Gene Therapy Bioassay Service Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Pacific BioLabs
6.4.1. Company Overview
6.4.2. Cell and Gene Therapy Bioassay Service Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. PPD Laboratories
6.5.1. Company Overview
6.5.2. Cell and Gene Therapy Bioassay Service Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. WuXi Advanced Therapies
6.6.1. Company Overview
6.6.2. Cell and Gene Therapy Bioassay Service Portfolio
6.6.3. Recent Developments and Future Outlook
7. CELL AND GENE THERAPY BIOASSAY SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC: COMPANY PROFILES
7.1. Chapter Overview
7.2. AnaBioTec
7.2.1. Company Overview
7.2.2. Cell and Gene Therapy Bioassay Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. Intertek Pharmaceutical Services
7.3.1. Company Overview
7.3.2. Cell and Gene Therapy Bioassay Service Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. Lonza
7.4.1. Company Overview
7.4.2. Cell and Gene Therapy Bioassay Service Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. Porton Bio
7.5.1. Company Overview
7.5.2. Cell and Gene Therapy Bioassay Service Portfolio
7.5.3. Recent Developments and Future Outlook
8. MARKET TREND ANALYSIS
8.1. Chapter Overview
8.2 Cell and Gene Therapy Bioassay Service Providers: Analysis by Type of Bioanalytical Service(s) Offered and Application Area
8.3. Cell and Gene Therapy Bioassay Service Providers: Analysis by Type of Bioassay(s) and Type of Bioanalytical Service(s) Offered
8.4 Cell and Gene Therapy Bioassay Service Providers: Analysis by Location of Bioanalytical facilities
8.4.1. Players with Bioanalytical Facilities in US
8.4.2. Players with Bioanalytical Facilities in Rest of the World
9. GLOBAL EVENT AND STRATEGIC INITIATIVE ANALYSIS
9.1. Chapter Overview
9.2. Cell and Gene Therapy Bioassay Service Providers: List of Event and Strategic Initiatives
9.2.1. Analysis by Year of Event
9.2.2. Analysis by Type of Event
9.2.3. Analysis by Year and Type of Event
9.2.4. Analysis by Type of Services Involved
9.2.5. Analysis by Application Area
9.2.6. Prominent Players: Analysis by Number of Events and Strategic Initiatives
10. CASE STUDY: MARKET LANDSCAPE OF CELL AND GENE THERAPIES
10.1. Chapter Overview
10.2. Cell Therapy Market
10.2.1. T-Cell Immunotherapies: Development Pipeline
10.2.1.1. Analysis by Type of Product
10.2.2. CAR-T Cell Therapies: Development Pipeline
10.2.2.1. Analysis by Phase of Development
10.2.2.2. Analysis by Therapeutic Area
10.2.2.3. Analysis by Type of Developer
10.2.2.4. Key Industry Players: Analysis by Number of CAR-T Cell Therapies in Development
10.2.3. TCR-based Therapies: Development Pipeline
10.2.3.1. Analysis by Phase of Development
10.2.3.2. Analysis by Therapeutic Area
10.2.3.3. Analysis by Type of Developer
10.2.3.4. Key Industry Players: Analysis by Number of TCR-based Therapies in Development
10.2.4. TIL-based Therapies: Development Pipeline
10.2.4.1. Analysis by Phase of Development
10.2.4.2. Analysis by Therapeutic Area
10.2.4.3. Analysis by Type of Developer
10.2.4.4. Key Industry Players: Analysis by Number of TIL-based Therapies in Development
10.3. Gene Therapy Market
10.3.1. Gene Therapy Market: Clinical and Commercial Pipeline
10.3.1.1. Analysis by Phase of Development
10.3.1.2. Analysis by Therapeutic Area
10.3.2. Gene Therapy Market: Development Pipeline
10.3.2.1. Analysis by Phase of Development
10.3.2.2. Analysis by Therapeutic Area
11. LIKELY PARTNERS FOR CELL THERAPY BIOASSAY SERVICE PROVIDERS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Potential Strategic Partners for Cell Therapy Bioassay Service Providers
11.3.1. Likely Partner Opportunities for Stem Cell Therapy Bioassay Service Providers
11.3.2. Likely Partner Opportunities for CAR-T Therapy Bioassay Service Providers
11.3.3. Likely Partner Opportunities for Dendritic Cell Therapy Bioassay Service Providers
11.3.4. Likely Partner Opportunities for Tumor Cell Therapy Bioassay Service Providers
11.3.5. Likely Partner Opportunities for NK Cell Therapy Bioassay Service Providers
12. LIKELY PARTNERS FOR GENE THERAPY BIOASSAY SERVICE PROVIDERS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Potential Strategic Partners for Gene Therapy Bioassay Service Providers
12.3.1. Likely Partner Opportunities in North America
12.3.2. Likely Partner Opportunities in Europe
12.3.3. Likely Partner Opportunities in Asia-Pacific
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Cell and Gene Therapy Bioassay Services Market
13.3.1. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Type of Therapy
13.3.2. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Therapeutic Area
13.3.3. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Scale of Operation
13.3.4. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Geography
13.4. Cell Therapy Bioassay Services Market in North America, 2021-2030
13.4.1. Cell Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2030
13.4.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2030
13.4.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2030
13.4.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2030
13.4.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2030
13.4.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2030
13.4.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2030
13.4.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2030
13.4.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2030
13.4.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2030
13.4.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2030
13.4.2. Cell Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2030
13.4.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2030
13.4.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2030
13.4.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2030
13.5. Cell Therapy Bioassay Services Market in Europe, 2021-2030
13.5.1. Cell Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2030
13.5.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2030
13.5.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2030
13.5.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2030
13.5.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2030
13.5.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2030
13.5.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2030
13.5.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2030
13.5.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2030
13.5.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2030
13.5.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2030
13.5.2. Cell Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2030
13.5.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2030
13.5.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2030
13.5.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in Europe, 2021-2030
13.6. Cell Therapy Bioassay Services Market in Asia-Pacific, 2021-2030
13.6.1. Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2030
13.6.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2030
13.6.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2030
13.6.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030
13.6.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2030
13.6.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030
13.6.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2030
13.6.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2030
13.6.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2030
13.6.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2030
13.6.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030
13.6.2. Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2030
13.6.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2030
13.6.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2030
13.6.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2030
13.7. Cell Therapy Bioassay Services Market in Latin America, 2021-2030
13.7.1. Cell Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2030
13.7.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2030
13.7.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2030
13.7.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2030
13.7.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2030
13.7.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2030
13.7.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2030
13.7.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2030
13.7.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2030
13.7.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2030
13.7.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2030
13.7.2. Cell Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2030
13.7.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2030
13.7.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2030
13.7.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2030
13.8. Cell Therapy Bioassay Services Market in MENA, 2021-2030
13.8.1. Cell Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2030
13.8.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2030
13.8.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2030
13.8.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2030
13.8.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2030
13.8.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2030
13.8.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2030
13.8.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2030
13.8.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2030
13.8.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2030
13.8.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2030
13.8.2. Cell Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2030
13.8.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2030
13.8.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2030
13.8.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2030
13.9. Gene Therapy Bioassay Services Market in North America, 2021-2030
13.9.1. Gene Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2030
13.9.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2030
13.9.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2030
13.9.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2030
13.9.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2030
13.9.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2030
13.9.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2030
13.9.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2030
13.9.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2030
13.9.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2030
13.9.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2030
13.9.2. Gene Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2030
13.9.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2030
13.9.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2030
13.9.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2030
13.10. Gene Therapy Bioassay Services Market in Europe, 2021-2030
13.10.1. Gene Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2030
13.10.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2030
13.10.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2030
13.10.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2030
13.10.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2030
13.10.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2030
13.10.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2030
13.10.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2030
13.10.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2030
13.10.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2030
13.10.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2030
13.10.2. Gene Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2030
13.10.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2030
13.10.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2030
13.10.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in Europe, 2021-2030
13.11. Gene Therapy Bioassay Services Market in Asia-Pacific, 2021-2030
13.11.1. Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2030
13.11.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2030
13.11.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2030
13.11.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030
13.11.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2030
13.11.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030
13.11.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2030
13.11.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2030
13.11.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2030
13.11.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2030
13.11.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030
13.11.2. Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2030
13.11.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2030
13.11.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2030
13.11.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2030
13.12. Gene Therapy Bioassay Services Market in Latin America, 2021-2030
13.12.1. Gene Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2030
13.12.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2030
13.12.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2030
13.12.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2030
13.12.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2030
13.12.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2030
13.12.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2030
13.12.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2030
13.12.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2030
13.12.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2030
13.12.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2030
13.12.2. Gene Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2030
13.12.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2030
13.12.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2030
13.12.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2030
13.13. Gene Therapy Bioassay Services Market in MENA, 2021-2030
13.13.1. Gene Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2030
13.13.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2030
13.13.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2030
13.13.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2030
13.13.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2030
13.13.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2030
13.13.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2030
13.13.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2030
13.13.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2030
13.13.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2030
13.13.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2030
13.13.2. Gene Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2030
13.13.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2030
13.13.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2030
13.13.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2030
14. CONCLUSION
14.1. Chapter Overview
15. EXECUTIVE INSIGHTS16. APPENDIX 1: TABULATED DATA17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 4D Molecular Therapeutics
  • AavantiBio
  • aaVective
  • AAVogen
  • AbbVie
  • AbClon
  • Abeona Therapeutics
  • Absorption Systems
  • Adaptimmune Therapeutics
  • Adelson Medical Research Foundation (AMRF)
  • Adicet Bio
  • Advanced Cell Diagnostics
  • Advantagene
  • Advaxis
  • Adverum Biotechnologies
  • Aeon Therapeutics
  • Affinia Therapeutics
  • AffyImmune Therapeutics
  • Agency for Science, Technology and Research (A*STAR)
  • AgenTus Therapeutics
  • AGTC
  • AIT Bioscience
  • Akouos
  • Allergan
  • Allogene Therapeutics
  • AlphaVax
  • Altasciences
  • Altheia Science
  • Altor Bioscience 
  • Amarna Therapeutics
  • Ambulero
  • American Gene Technologies
  • Amgen
  • Amicus Therapeutics
  • AnaBioTec
  • Anaeropharma Science
  • AnGes
  • Angionetics
  • AnHui Medical University (AHMU)
  • ApolloBio
  • Applied StemCell
  • Arbele
  • Aruvant Sciences
  • ASC Therapeutics
  • Asklepios BioPharmaceutical (AskBio)
  • Atara Biotherapeutics
  • Atsena Therapeutics
  • Aurigon
  • Aurora Biopharma
  • Avance Biosciences
  • Avectas 
  • Avomeen
  • AVROBIO
  • Axovant Gene Therapies
  • Baylor College of Medicine
  • BD Biosciences
  • Beam Therapeutics
  • Beijing 302 Hospital
  • Beijing Boren Hospital
  • Beijing Children's Hospital
  • Bellicum Pharmaceuticals 
  • BioAgilytix
  • BioAnalytix
  • Biogen
  • BioMarin Pharmaceutical
  • BioTether Sciences
  • BioVec Pharma
  • bluebird bio
  • BridgeBio
  • Bristol-Myers Squibb
  • California Institute of Technology
  • Cambridge Gene Therapy
  • Carmine Therapeutics
  • Cartesian Therapeutics
  • Cartherics
  • Castle Creek Biosciences
  • Catalent
  • Catalyst Biosciences
  • CavoGene LifeSciences
  • CCRM
  • Celgene
  • Cell Therapy Catapult
  • Cellectis
  • CellGenTech
  • Cellular Biomedicine 
  • Celonic
  • Celsion
  • CG Oncology
  • Changhai Hospital
  • Charles River Laboratories
  • Children's Hospital of Philadelphia
  • China Immunotech Biotechnology
  • Chinese PLA General Hospital
  • City of Hope
  • Clean Cells
  • CODA Biotherapeutics
  • Cognate BioServices
  • CombiGene
  • Copenhagen University Hospital
  • Copernicus Therapeutics
  • Creative Biolabs
  • CRISPR Therapeutics
  • CSL Behring
  • Cynvec
  • Cyprium Therapeutics
  • Cytovant Sciences
  • Daiichi Sankyo 
  • DiNAQOR
  • DNAlite Therapeutics
  • DNAtrix
  • Duke University School of Medicine
  • Earle A. Chiles Research Institute
  • Editas Medicine
  • Emendo Biotherapeutics
  • Encoded Therapeutics
  • Endsulin
  • Enochian BioSciences
  • Entos Pharmaceuticals
  • Epeius Biotechnologies
  • Errant Gene Therapeutics
  • Esteve
  • Eurofins DiscoverX
  • Evotec
  • Excision BioTherapeutics
  • Exegenesis Bio
  • Expression Therapeutics
  • Eyevensys
  • FerGene
  • Ferring Pharmaceuticals
  • Flash Therapeutics
  • Flexion Therapeutics
  • Fortress Biotech
  • Fosun Pharma
  • Fred Hutchinson Cancer Research Center
  • Freeline Therapeutics
  • Fujian Cancer Hospital
  • Fujian Medical University
  • Gemini Therapeutics
  • Gene Therapy Research Institution
  • GeneCure Biotechnologies
  • Genelux
  • GeneMedicine
  • GeneQuine Biotherapeutics
  • Generation Bio
  • Genethon
  • Genocea
  • Genprex
  • GenSight Biologics
  • GenVec
  • GlaxoSmithKline
  • Glycostem Therapeutics
  • GOG Foundation
  • Gradalis
  • Gyros Protein Technologies
  • Gyroscope Therapeutics
  • Hadassah Medical Organization
  • Handl Therapeutics
  • Hebei Senlang Biotechnology
  • Helixmith
  • Hemera Biosciences
  • Henan Cancer Hospital
  • Henan Provincial People's Hospital
  • Herantis Pharma
  • Herlev Hospital
  • HiTech Health
  • Holostem Terapie Avanzate
  • Homology Medicines
  • HORAMA
  • Huapont Life Sciences
  • Human Stem Cells Institute PJSC (HSCI)
  • Ikarovec
  • Ilya Pharma
  • Immatics
  • Immunocore
  • ImmunXperts
  • Immusoft
  • Incyte
  • Inovio Pharmaceuticals
  • Intellia Therapeutics
  • Intertek
  • Invectys
  • Iovance Biotherapeutics
  • IVERIC bio
  • James and Esther King Biomedical Research Program
  • Janssen
  • JOINN Laboratories 
  • Jonsson Comprehensive Cancer Center
  • Juno Therapeutics
  • Junshi Biosciences 
  • JW Therapeutics
  • KAEDI
  • Karolinska Institute
  • Key Biologics
  • Kite Pharma
  • Kodikaz Therapeutic Solutions
  • Kolon TissueGene
  • Kriya Therapeutics
  • Krystal Biotech
  • KSQ Therapeutics
  • Kubota Vision
  • Kuur Therapeutics
  • Labcorp
  • Leiden University Medical Center
  • LentiStem Biotech
  • LEXEO Therapeutics
  • Limelight Bio
  • Lion TCR
  • Living Pharma
  • LogicBio Therapeutics
  • Lokon Pharma
  • Lonza
  • Lysogene
  • Lytix Biopharma
  • Masonic Cancer Center
  • MD Anderson Cancer Center
  • Medigene
  • MeiraGTx
  • Memorial Sloan-Kettering Cancer Center
  • Merck
  • Merck KGaA
  • Mesoblast
  • Mie University
  • Milo Biotechnology
  • Miltenyi Biomedicine
  • MingJu Therapeutics
  • Mitsubishi Tanabe Pharma
  • Momotaro-Gene
  • MultiVir
  • Mustang Bio
  • Myosana Therapeutics
  • Nanjing Medical University
  • Nantes University Hospital
  • National Cancer Institute
  • Navega Therapeutics
  • NeuExcell Therapeutics
  • Neuracle Genetics
  • Neurogene
  • Neurophth Therapeutics
  • Nexelis
  • Ninevah Therapeutics
  • Ningbo Cancer Hospital
  • Noga Therapeutics 
  • Novartis
  • Ocugen
  • Oncolys BioPharma
  • Onconetics Pharmaceuticals
  • OncoSec
  • OncoSenX
  • ORCA Therapeutics
  • Orchard Therapeutics
  • Oxford Biomedica
  • OXGENE
  • Oxular
  • Pacific BioLabs
  • PACT Pharma
  • PAIRimmune 
  • Passage Bio
  • Pattern Biosciences
  • PeriphaGen
  • Peter MacCallum Cancer Centre
  • Pfizer
  • Phio Pharmaceuticals
  • Phoenix Nest
  • PhorMed
  • PolyBioCept
  • Porton Bio
  • Poseida Therapeutics
  • PPD Laboratories
  • Precigen
  • Precision BioSciences
  • Precision for Medicine
  • Prevail Therapeutics
  • Prometheus Laboratories
  • Providence
  • PsiOxus Therapeutics
  • PTC Therapeutics
  • Public Health England (PHE)
  • Q2 Solutions
  • QualTex Laboratories
  • R&D systems
  • Reading Scientific Services
  • Redbiotec
  • Redpin Therapeutics
  • Regeneron Pharmaceuticals
  • REGENXBIO
  • Renova Therapeutics
  • resTORbio
  • Ring Therapeutics
  • Rocket Pharmaceuticals
  • Roswell Park Cancer Institute
  • Ruijin Hospital
  • San Raffaele Telethon Institute For Gene Therapy
  • Sangamo Therapeutics
  • Sarepta Therapeutics
  • SBH Sciences
  • Scancell
  • Selecta Biosciences
  • SGS
  • Shanghai Cell Therapy Research Institute
  • Shanghai Children's Medical Center
  • Shanghai Sunway Biotech
  • Shanghai Unicar-Therapy Bio-medicine Technology
  • Sheba Medical Center
  • Shenzhen BinDeBio
  • Shenzhen Geno-immune Medical Institute
  • Sibiono GeneTech
  • Sidney Kimmel Comprehensive Cancer Center
  • Siemens Healthineers
  • Sinobioway Cell Therapy
  • Solid Biosciences
  • Solvias
  • Soochow University
  • Sorrento Therapeutics
  • Spark Therapeutics
  • Spirovant Sciences
  • SpringWorks Therapeutics
  • St. Jude Children’s Research Hospital
  • STEMCELL Technologies
  • StrideBio
  • Sun Yat-sen University
  • Svar Life Science
  • SwanBio Therapeutics
  • Takara Bio
  • Targovax
  • TCR2 Therapeutics
  • TCRCure Biopharma
  • Tenaya Therapeutics
  • Tessa Therapeutics
  • Texcell
  • The First Affiliated Hospital of Zhejiang University
  • The Leukemia and Lymphoma Society
  • The Methodist Hospital System
  • The Netherlands Cancer Institute
  • The Ohio State University Comprehensive Cancer Center 
  • Pregene Biotechnology
  • The Seventh Affiliated Hospital
  • TheraBiologics
  • THERAVECTYS
  • Third Military Medical University
  • Tmunity Therapeutics
  • Tolerion
  • TrakCel
  • Transgene
  • Trizell
  • Trucode Gene Repair
  • UAB (Universitat Autònoma de Barcelona)
  • Ultragenyx Pharmaceutical
  • UNC Lineberger Comprehensive Cancer Center 
  • uniQure
  • University College London
  • University Health Network
  • University of Connecticut
  • University of Manchester
  • University of Minnesota
  • University of Munich
  • University of Pennsylvania
  • University of Pittsburgh
  • University of Southern California
  • Uppsala University
  • Urovant Sciences
  • UWELL Biopharma
  • VBL Therapeutics
  • VCN Biosciences
  • Verve Therapeutics
  • ViGeneron
  • Vivet Therapeutics
  • Voyager Therapeutics
  • Wellington Zhaotai Therapies
  • Wize Pharma
  • WuXi Advanced Therapies
  • WuXi AppTec
  • Wyvern Pharmaceuticals
  • Xiangxue Life Sciences
  • Xinqiao Hospital
  • Xuanwu Hospital
  • XyloCor Therapeutics
  • Yale University
  • Zelluna Immunotherapy
  • Zhujiang Hospital
  • Ziopharm Oncology

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Cell and Gene Therapy Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend and Growth Opportunity Analysis Report Coverage: By Type, Services, Scale, Service Providers, End User and Geography - Product Image

Cell and Gene Therapy Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend and Growth Opportunity Analysis Report Coverage: By Type, Services, Scale, Service Providers, End User and Geography

  • Report
  • 232 Pages
  • Global
From
Gene Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Gene Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-users and Key Geographical Regions - Product Image

Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-users and Key Geographical Regions

  • Report
  • 343 Pages
  • Global
From
Cell & Gene Therapy Bioanalytical Testing Services Market Size, Share & Trends Analysis Report by Test Type (Bioavailability & Bioequivalence Studies), Product Type, Stage Of Development By Product Type, Indication, Region, and Segment Forecasts, 2024-2030 - Product Image

Cell & Gene Therapy Bioanalytical Testing Services Market Size, Share & Trends Analysis Report by Test Type (Bioavailability & Bioequivalence Studies), Product Type, Stage Of Development By Product Type, Indication, Region, and Segment Forecasts, 2024-2030

  • Report
  • 261 Pages
  • Global
From
Gene Therapy Global Market Report 2024 - Product Image

Gene Therapy Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.